ArticleCell reports2024

Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.

Ryan Blawski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.